Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Accentia Biopharmaceuticals has entered into definitive agreements for an approximate $8.5 million private placement offering of secured convertible debentures and common stock purchase warrants to existing institutional investors.
Subscribe to our email newsletter
The debentures are convertible into company common stock at $1.10 per share. After six months, the debentures will amortize through thirty equal installments. The company may at its option redeem the debentures for an amount equal to 110% of the then outstanding principal.
The debentures were issued at an 8% original issue discount and bear interest at an annual rate of 8% payable monthly commencing one year from closing. The offering includes the issuance of warrants, giving holders the right to purchase approximately 2.8 million shares of company common stock, exercisable at $1.21 per share with a six-year term.
Accentia intends to use the proceeds to support development, regulatory and partnering strategies for SinuNase and Revimmune and support general operations.